<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34468173</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>22</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans.</ArticleTitle><Pagination><StartPage>e0105521</StartPage><MedlinePgn>e0105521</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01055-21</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01055-21</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) is one of the major etiological agents of hand, foot, and mouth disease (HFMD), and infection occasionally leads to fatal neurological complications in children. However, only inactivated whole-virus vaccines against EV-A71 are commercially available in Mainland China. Furthermore, the mechanisms underlying the infectivity and pathogenesis of EV-A71 remain to be better understood. By adaptation of an EV-A71 B5 strain in monkey Vero cells in the presence of brilliant black BN (E151), an anti-EV-A71 agent, a double mutant with VP1-V238A,K244R emerged whose infection was enhanced by E151. The growth of the reverse genetics (RG) mutant RG/B5-VP1-V238A,K244R (RG/B5-AR) was promoted by E151 in Vero cells but inhibited in other human and murine cells, while its parental wild type, RG/B5-wt, was strongly prevented by E151 from infection in all tested cells. In the absence of E151, RG/B5-AR exhibited defective cell entry/exit, resulting in reduced viral transmission and growth <i>in vitro</i>. It had augmented binding affinity to sulfated glycans, cells, and tissue/organs, which probably functioned as decoys to restrict viral dissemination and infection. RG/B5-AR was also attenuated, with a 355 times higher 50% lethal dose (LD<sub>50</sub>) and a shorter timing of virus clearance than those of RG/B5-wt in suckling AG129 mice. However, it remained highly immunogenic in adult AG129 mice and protected their suckling mice from lethal EV-A71 challenges through maternal neutralizing antibodies. Overall, discovery of the attenuated mutant RG/B5-AR contributes to better understanding of virulence determinants of EV-A71 and to further development of novel vaccines against EV-A71. <b>IMPORTANCE</b> Enterovirus A71 (EV-A71) is highly contagious in children and has been responsible for thousands of deaths in Asia-Pacific region since the 1990s. Unfortunately, the virulence determinants and pathogenesis of EV-A71 are not fully clear. We discovered that a novel EV-A71 mutant, VP1-V238A,K244R, showed growth attenuation with reduced efficiency of cell entry/exit. In the Vero cell line, which has been approved for manufacturing EV-A71 vaccines, the growth defects of the mutant were compensated by a food dye, brilliant black BN. The mutant also showed augmented binding affinity to sulfated glycans and other cellular components, which probably restricted viral infection and dissemination. Therefore, it was virulence attenuated in a mouse model but still retained its immunogenicity. Our findings suggest the mutant as a promising vaccine candidate against EV-A71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2740-9901</Identifier><AffiliationInfo><Affiliation>Temasek Life Sciences Laboratorygrid.226688.0, Limited, Republic of Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singaporegrid.4280.e, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Sek-Man</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Temasek Life Sciences Laboratorygrid.226688.0, Limited, Republic of Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singaporegrid.4280.e, Republic of Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NUS Suzhou Research Institute, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Kaw-Bing</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Temasek Life Sciences Laboratorygrid.226688.0, Limited, Republic of Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Temasek Life Sciences Laboratory (TLL)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041681" MajorTopicYN="N">NIH 3T3 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cell-adapted mutants</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">live attenuated vaccines</Keyword><Keyword MajorTopicYN="N">sulfated glycans</Keyword><Keyword MajorTopicYN="N">virulence determinants</Keyword><Keyword MajorTopicYN="N">virus dissemination</Keyword><Keyword MajorTopicYN="N">virus entry/exit</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34468173</ArticleId><ArticleId IdType="pmc">PMC8549518</ArticleId><ArticleId IdType="doi">10.1128/JVI.01055-21</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP, Jr, Kennett ML, Pallansch MA. 1999. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73:9969&#x2013;9975. 10.1128/JVI.73.12.9969-9975.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.12.9969-9975.1999</ArticleId><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessaud M, Razafindratsimandresy R, Nougairede A, Joffret ML, Deshpande JM, Dubot-Peres A, Heraud JM, de Lamballerie X, Delpeyroux F, Bailly JL. 2014. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One 9:e90624. 10.1371/journal.pone.0090624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090624</ArticleId><ArticleId IdType="pmc">PMC3944068</ArticleId><ArticleId IdType="pubmed">24598878</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena VK, Sane S, Nadkarni SS, Sharma DK, Deshpande JM. 2015. Genetic diversity of enterovirus A71, India. Emerg Infect Dis 21:123&#x2013;126. 10.3201/eid2101.140743.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2101.140743</ArticleId><ArticleId IdType="pmc">PMC4285237</ArticleId><ArticleId IdType="pubmed">25531549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY. 1998. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 352:1391. 10.1016/s0140-6736(05)60789-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(05)60789-1</ArticleId><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. 1999. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341:936&#x2013;942. 10.1056/NEJM199909233411302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411302</ArticleId><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S. 2001. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32:236&#x2013;242. 10.1086/318454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/318454</ArticleId><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778&#x2013;790. 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, Long L, Luo L, Li Y, Leung GM, Cowling BJ, Yu H. 2017. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill
22(50):pii=16-00824. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.50.16-00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox JA, Hiscox JA, Solomon T, Ooi MH, Ng LFP. 2017. Immunopathogenesis and virus-host interactions of enterovirus 71 inpatients with hand, foot and mouth disease. Front Microbiol 8:2249. 10.3389/fmicb.2017.02249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02249</ArticleId><ArticleId IdType="pmc">PMC5713468</ArticleId><ArticleId IdType="pubmed">29238324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC. 2016. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev Vaccines 15:803&#x2013;813. 10.1080/14760584.2016.1191357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2016.1191357</ArticleId><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024&#x2013;2032. 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Wang J, Li Q. 2014. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 370:829&#x2013;837. 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, Li J, Wang S, Hu Y, Gu S, Zhang J, Yao G, Gu J, Wang X, Zhou Y, Chen C, Zhang M, Cao M, Wang J, Wang H, Wang N. 2014. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370:818&#x2013;828. 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. 2015. Review of enterovirus 71 vaccines. Clin Infect Dis 60:797&#x2013;803. 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Shimizu H, Nagata N, Ami Y, Suzaki Y, Sata T, Iwasaki T, Miyamura T. 2005. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol 86:1391&#x2013;1401. 10.1099/vir.0.80784-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.80784-0</ArticleId><ArticleId IdType="pubmed">15831951</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. 2007. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81:9386&#x2013;9395. 10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kwang J. 2014. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol 88:5803&#x2013;5815. 10.1128/JVI.00289-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00289-14</ArticleId><ArticleId IdType="pmc">PMC4019108</ArticleId><ArticleId IdType="pubmed">24623423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee PTI, Tan SH, Ong KC, Tan KO, Wong KT, Hassan SS, Poh CL. 2019. Development of live attenuated enterovirus 71 vaccine strains that confer protection against lethal challenge in mice. Sci Rep 9:4805. 10.1038/s41598-019-41285-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41285-z</ArticleId><ArticleId IdType="pmc">PMC6423319</ArticleId><ArticleId IdType="pubmed">30886246</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai YH, Huang SW, Hsieh WS, Cheng CK, Chang CF, Wang YF, Wang JR. 2019. Enterovirus A71 containing codon-deoptimized VP1 and high-fidelity polymerase as next-generation vaccine candidate. J Virol 93:e02308-18. 10.1128/JVI.02308-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02308-18</ArticleId><ArticleId IdType="pmc">PMC6580961</ArticleId><ArticleId IdType="pubmed">30996087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798&#x2013;801. 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794&#x2013;797. 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611&#x2013;620. 10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J, Su D, Ni C, Li J, Rao Z, Liu L, Lou Z. 2014. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog 10:e1004422. 10.1371/journal.ppat.1004422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Sudaka Y, Takashino A, Imura A, Fujii K, Koike S. 2018. Amino acid variation at VP1-145 of enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J Virol 92:e00681-18. 10.1128/JVI.00681-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00681-18</ArticleId><ArticleId IdType="pmc">PMC6052303</ArticleId><ArticleId IdType="pubmed">29848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Sudaka Y, Takashino A, Kobayashi K, Kataoka C, Suzuki T, Iwata-Yoshikawa N, Kotani O, Ami Y, Shimizu H, Nagata N, Mizuta K, Matsuzaki Y, Koike S. 2018. VP1 Amino acid residue 145 of enterovirus 71 is a key residue for its receptor attachment and resistance to neutralizing antibody during cynomolgus monkey infection. J Virol 92:e00682-18. 10.1128/JVI.00682-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00682-18</ArticleId><ArticleId IdType="pmc">PMC6052295</ArticleId><ArticleId IdType="pubmed">29848582</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee HK, Tan CW, Yogarajah T, Lee MHP, Chai HJ, Hanapi NA, Yusof SR, Ong KC, Lee VS, Sam IC, Chan YF. 2019. Electrostatic interactions at the five-fold axis alter heparin-binding phenotype and drive enterovirus A71 virulence in mice. PLoS Pathog 15:e1007863. 10.1371/journal.ppat.1007863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007863</ArticleId><ArticleId IdType="pmc">PMC6881073</ArticleId><ArticleId IdType="pubmed">31730673</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Sam IC, Lee VS, Wong HV, Chan YF. 2017. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501:79&#x2013;87. 10.1016/j.virol.2016.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.11.009</ArticleId><ArticleId IdType="pubmed">27875780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaini Z, McMinn P. 2012. A single mutation in capsid protein VP1 (Q145E) of a genogroup C4 strain of human enterovirus 71 generates a mouse-virulent phenotype. J Gen Virol 93:1935&#x2013;1940. 10.1099/vir.0.043893-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.043893-0</ArticleId><ArticleId IdType="pubmed">22647370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka C, Suzuki T, Kotani O, Iwata-Yoshikawa N, Nagata N, Ami Y, Wakita T, Nishimura Y, Shimizu H. 2015. The role of VP1 amino acid residue 145 of enterovirus 71 in viral fitness and pathogenesis in a cynomolgus monkey model. PLoS Pathog 11:e1005033. 10.1371/journal.ppat.1005033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005033</ArticleId><ArticleId IdType="pmc">PMC4504482</ArticleId><ArticleId IdType="pubmed">26181772</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Tai CH, Fonville JM, Lin CH, Wang SM, Liu CC, Su IJ, Smith DJ, Wang JR. 2015. Mapping enterovirus A71 antigenic determinants from viral evolution. J Virol 89:11500&#x2013;11506. 10.1128/JVI.02035-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02035-15</ArticleId><ArticleId IdType="pmc">PMC4645677</ArticleId><ArticleId IdType="pubmed">26339057</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur Huang KY, Chen MF, Huang YC, Shih SR, Chiu CH, Lin JJ, Wang JR, Tsao KC, Lin TY. 2017. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nat Commun 8:762. 10.1038/s41467-017-00736-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00736-9</ArticleId><ArticleId IdType="pmc">PMC5624920</ArticleId><ArticleId IdType="pubmed">28970483</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Jia Q, Wong SM, Chua KB. 2019. In vitro and in vivo inhibition of infectivity of human enterovirus 71 by a sulfonated food azo dye, brilliant black BN. J Virol 93:e00061-19. 10.1128/JVI.00061-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00061-19</ArticleId><ArticleId IdType="pmc">PMC6694806</ArticleId><ArticleId IdType="pubmed">31167919</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Wong SM, Chua KB. 2021. Sulfonated azo dyes enhance the genome release of enterovirus A71 VP1-98K variants by preventing the virions from being trapped by sulfated glycosaminoglycans at acidic pH. Virology 555:19&#x2013;34. 10.1016/j.virol.2020.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.12.021</ArticleId><ArticleId IdType="pubmed">33422703</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, Ng JK, Chow VT, Alonso S. 2012. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86:2121&#x2013;2131. 10.1128/JVI.06103-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Moncla LH, Ronderos MD, Friedrich TC, Osorio JE. 2016. A single mutation in the VP1 of enterovirus 71 is responsible for increased virulence and neurotropism in adult interferon-deficient mice. J Virol 90:8592&#x2013;8604. 10.1128/JVI.01370-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01370-16</ArticleId><ArticleId IdType="pmc">PMC5021399</ArticleId><ArticleId IdType="pubmed">27440896</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Huang YH, Tsai HP, Kuo PH, Wang SM, Liu CC, Wang JR. 2017. A selective bottleneck shapes the evolutionary mutant spectra of enterovirus A71 during viral dissemination in humans. J Virol 91:e01062-17. 10.1128/JVI.01062-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01062-17</ArticleId><ArticleId IdType="pmc">PMC5686718</ArticleId><ArticleId IdType="pubmed">28931688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandary MB, Poh CL. 2018. Changes in the EV-A71 genome through recombination and spontaneous mutations: impact on virulence. Viruses 10:320. 10.3390/v10060320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10060320</ArticleId><ArticleId IdType="pmc">PMC6024729</ArticleId><ArticleId IdType="pubmed">29895721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang PY, Chong CWH, Alonso S. 2021. Viral determinants that drive enterovirus-A71 fitness and virulence. Emerg Microbes Infect 10:713&#x2013;724. 10.1080/22221751.2021.1906754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1906754</ArticleId><ArticleId IdType="pmc">PMC8043536</ArticleId><ArticleId IdType="pubmed">33745413</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CK, Wu SR, Chen YC, Lee KJ, Chung NH, Lu YJ, Yu SL, Liu CC, Chow YH. 2018. Mutations in VP1 and 5&#x2032;-UTR affect enterovirus 71 virulence. Sci Rep 8:6688. 10.1038/s41598-018-25091-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25091-7</ArticleId><ArticleId IdType="pmc">PMC5923339</ArticleId><ArticleId IdType="pubmed">29703921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. 1998. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156&#x2013;167. 10.1002/(SICI)1521-1878(199802)20:2&lt;156::AID-BIES8&gt;3.0.CO;2-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1521-1878(199802)20:2&lt;156::AID-BIES8&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">9631661</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie SR, Warrington KH, Jr, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77:6995&#x2013;7006. 10.1128/jvi.77.12.6995-7006.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.12.6995-7006.2003</ArticleId><ArticleId IdType="pmc">PMC156206</ArticleId><ArticleId IdType="pubmed">12768018</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinson M, van der Merwe PA, Kelm S, May A, Jones EY, Crocker PR. 1996. Characterization of the sialic acid-binding site in sialoadhesin by site-directed mutagenesis. J Biol Chem 271:9267&#x2013;9272. 10.1074/jbc.271.16.9267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.16.9267</ArticleId><ArticleId IdType="pubmed">8621587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Lobigs M. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 76:4901&#x2013;4911. 10.1128/jvi.76.10.4901-4911.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.76.10.4901-4911.2002</ArticleId><ArticleId IdType="pmc">PMC136177</ArticleId><ArticleId IdType="pubmed">11967307</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickells J, Cannella M, Droll DA, Liang Y, Wold WS, Chambers TJ. 2008. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J Virol 82:12510&#x2013;12519. 10.1128/JVI.00458-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00458-08</ArticleId><ArticleId IdType="pmc">PMC2593324</ArticleId><ArticleId IdType="pubmed">18842715</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kiener TK, Kwang J. 2012. RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol J 9:238. 10.1186/1743-422X-9-238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-238</ArticleId><ArticleId IdType="pmc">PMC3493273</ArticleId><ArticleId IdType="pubmed">23072515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>